Synonyms: CI-9148 | Cystagon® | Cystaran® | cysteamine hydrochloride | L-1573
mercaptamine is an approved drug (FDA (1994), EMA (1997))
Compound class:
Synthetic organic
Comment: Mercaptamine is the simplest stable aminothiol, and a degradation product of the amino acid cysteine.
|
|
No information available. |
Summary of Clinical Use ![]() |
The bitartrate and hydrochloride salt forms are indicated for the treatment of neuropathic cystinosis, and to treat radiation sickness. Link to ClinicalTrials.gov to view currently registered trials assessing efficacy of this drug for additional indications. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The inherited lysosomal storage disease, cystinosis is characterized by the abnormal accumulation of the amino acid cystine and arises through inheritance of mutations in the lysosomal cystine transporter gene (CTNS, O60931). Intracellular cystine accumulation and crystallization causes widespread tissue damage. The free thiol group of cysteamine cleaves the disulphide bond in cystine, thereby allowing excretion of the cystine byproducts. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) European Medicines Agency (EMA) |